 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...496497498499500501502503504505506507508» |
- bortezomib / Generic mfg.
New P2 trial, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 14, 2013
P2, N=17, Recruiting, Sponsor: Stanford University
- ||||||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion: NSABP B-30: Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes (clinicaltrials.gov) - Jan 10, 2013
P3, N=5351, Completed, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial withdrawal: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jan 8, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Completed --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jan 8, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Completed --> Withdrawn N=50 --> 0
- |||| Decadron (dexamethasone) / Merck (MSD)
Enrollment open, CINV: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) (clinicaltrials.gov) - Jan 7, 2013
P4, N=492, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=50 --> 0 Not yet recruiting --> Recruiting
- | ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Rituxan (rituximab) / Roche
Trial completion: CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 7, 2013
P=N/A, N=27, Completed, Sponsor: University of Nebraska
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| cyclophosphamide / Generic mfg.
Enrollment closed, FDG PET: R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 6, 2013
P2, N=55, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Metastases: Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Jan 6, 2013
P2, N=117, Active, not recruiting, Sponsor: University of Schleswig-Holstein
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jan 4, 2013
P1, N=37, Recruiting, Sponsor: North Central Cancer Treatment Group
Recruiting --> Active, not recruiting Suspended --> Recruiting
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed, Surgery: Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Jan 3, 2013
P3, N=1206, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Suspended --> Recruiting Completed --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: DA-EPOCH-R: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Jan 2, 2013
P=N/A, N=12, Recruiting, Sponsor: Baylor College of Medicine
- Enrollment open: Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer (clinicaltrials.gov) - Jan 2, 2013
P2, N=28, Recruiting, Sponsor: Leo W. Jenkins Cancer Center
Completed --> Active, not recruiting Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed, Surgery: Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. (clinicaltrials.gov) - Jan 2, 2013
P2, N=60, Active, not recruiting, Sponsor: University of Tennessee Cancer Institute
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial withdrawal: S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jan 1, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Withdrawn
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial termination: S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer (clinicaltrials.gov) - Jan 1, 2013
P3, N=602, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Withdrawn Completed --> Terminated; poor accrual
- Enrollment change: S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jan 1, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Completed --> Terminated; poor accrual N=90 --> 0
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer (clinicaltrials.gov) - Jan 1, 2013
P3, N=602, Terminated, Sponsor: Southwest Oncology Group
N=90 --> 0 N=1000 --> 602
- everolimus / Generic mfg.
Enrollment open: EVACEL: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (clinicaltrials.gov) - Jan 1, 2013
P2, N=72, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
N=1000 --> 602 Not yet recruiting --> Recruiting
- | Tasigna (nilotinib) / Novartis, Inhibikase
Trial initiation date: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Dec 23, 2012
P2, N=44, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Initiation date: Aug 2012 --> Dec 2012
- | Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment open: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Dec 23, 2012
P2, N=44, Recruiting, Sponsor: Mayo Clinic
Initiation date: Aug 2012 --> Dec 2012 Not yet recruiting --> Recruiting
- | Trial completion, Surgery: Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer (clinicaltrials.gov) - Dec 20, 2012
P3, N=633, Completed, Sponsor: Cancer and Leukemia Group B
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial termination: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 19, 2012
P2, N=62, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Doxorubicin and Bortezomib in Treating Patients With Liver Cancer (clinicaltrials.gov) - Dec 19, 2012
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- Genasense (oblimersen) / Genta
Trial termination, Combination therapy, IO biomarker, Metastases: Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 18, 2012
P1/2, N=69, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Adverse events: Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 16, 2012
P2, N=80, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Completed --> Terminated Recruiting --> Active, not recruiting
- | ifosfamide / Generic mfg., mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change: MRI Sarcoma Non Invasive Thermometry (clinicaltrials.gov) - Dec 13, 2012
P1/2, N=15, Completed, Sponsor: Mark Dewhirst
Recruiting --> Active, not recruiting N=30 --> 15 | Recruiting --> Completed
- | cyclophosphamide / Generic mfg., paclitaxel / Generic mfg.
New P2 trial, Surgery: Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer (clinicaltrials.gov) - Dec 13, 2012
P2, N=125, Recruiting, Sponsor: University of Nebraska
- ifosfamide / Generic mfg., mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: MRI Sarcoma Non Invasive Thermometry (clinicaltrials.gov) - Dec 13, 2012
P1/2, N=15, Completed, Sponsor: Mark Dewhirst
N=30 --> 15 | Recruiting --> Completed Recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Metastases: Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma (clinicaltrials.gov) - Dec 12, 2012
P2, N=36, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Recruiting --> Active, not recruiting
- doxorubicin hydrochloride / Generic mfg.
Enrollment open: Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=50, Recruiting, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Pinorubin (pirarubicin) / Sanofi
New P4 trial: CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma (clinicaltrials.gov) - Dec 9, 2012
P4, N=200, Recruiting, Sponsor: Ruijin Hospital
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2012
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
- Avastin (bevacizumab) / Roche
New P1 trial: Bevacizumab/Doxorubicin/Radiation for Sarcoma (clinicaltrials.gov) - Dec 6, 2012
P1, N=18, Recruiting, Sponsor: Massachusetts General Hospital
- sunitinib / Generic mfg.
Enrollment change: Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer (clinicaltrials.gov) - Dec 5, 2012
P=N/A, N=23, Active, not recruiting, Sponsor: Indiana University
Not yet recruiting --> Recruiting N=30 --> 23
- || Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Combination therapy, Metastases: A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2012
P1, N=111, Active, not recruiting, Sponsor: GlaxoSmithKline
N=30 --> 23 Recruiting --> Active, not recruiting
- | abexinostat (CG-781) / Xynomic
Enrollment closed, Combination therapy, Metastases: PCI-24781 in Combination With Doxorubicin to Treat Sarcoma (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=47, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Trial completion: A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer (clinicaltrials.gov) - Dec 2, 2012
P3, N=2611, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial termination: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Nov 29, 2012
P2, N=16, Terminated, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Completed --> Terminated; slow accrual
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Nov 29, 2012
P2, N=16, Terminated, Sponsor: Eastern Cooperative Oncology Group
Completed --> Terminated; slow accrual N=37 --> 16
- | Avastin (bevacizumab) / Roche, Rituxan (rituximab) / Roche
Trial termination, Combination therapy: A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Nov 27, 2012
P3, N=787, Terminated, Sponsor: Hoffmann-La Roche
N=37 --> 16 Completed --> Terminated; Due to an unfavorable benefit/risk ratio.
- | New P2 trial: Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer (clinicaltrials.gov) - Nov 22, 2012
P2, N=60, Recruiting, Sponsor: Hospital Affiliated to Military Medical Science, Beijing
- || New P3 trial: International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours (EUDRACT) - Nov 18, 2012
P3, N=600, Ongoing, Sponsor: University of Birmingham
- Avastin (bevacizumab) / Roche, Rituxan (rituximab) / Roche
Trial completion, Metastases: Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Nov 15, 2012
P2, N=73, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Due to an unfavorable benefit/risk ratio. Active, not recruiting --> Completed
- everolimus / Generic mfg.
Enrollment open, Combination therapy: Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (clinicaltrials.gov) - Nov 14, 2012
P1, N=42, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Enrollment change, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Nov 7, 2012
P2, N=7, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting N=44 --> 7
- |||||||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
New P3 trial: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a (clinicaltrials.gov) - Nov 7, 2012
P3, N=900, Recruiting, Sponsor: Hoffmann-La Roche
- Trial completion, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Nov 7, 2012
P2, N=7, Completed, Sponsor: City of Hope Medical Center
N=44 --> 7 Active, not recruiting --> Completed
- Adcetris (brentuximab vedotin) / Seagen, Takeda, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial initiation date, Metastases: Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma (clinicaltrials.gov) - Nov 6, 2012
P2, N=100, Recruiting, Sponsor: University of Cologne
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Oct 2012
- Adcetris (brentuximab vedotin) / Seagen, Takeda, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment open, Metastases: Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma (clinicaltrials.gov) - Nov 6, 2012
P2, N=100, Recruiting, Sponsor: University of Cologne
Initiation date: Jun 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- ||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion, Combination therapy: A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma (clinicaltrials.gov) - Nov 6, 2012
P1, N=51, Completed, Sponsor: Seattle Genetics, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed